Development of FABP4/5 inhibitors with potential therapeutic effect on type 2 Diabetes Mellitus
文献类型：期刊论文
| 作者 | He, Yu-Long1; Chen, Meng-Ting2,3; Wang, Ting2; Zhang, Ming-Ming1; Li, Ying-Xia1; Wang, He-Yao2 ; Ding, Ning1
|
| 刊名 | EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
 |
| 出版日期 | 2021-11-15 |
| 卷号 | 224页码:14 |
| 关键词 | Type 2 diabetes mellitus Dual FABP4/5 inhibitors Anti-lipolytic and anti-inflammatory effects Metabolic stability Anti-diabetic activities |
| ISSN号 | 0223-5234 |
| DOI | 10.1016/j.ejmech.2021.113720 |
| 通讯作者 | Li, Ying-Xia(liyx417@fudan.edu.cn) ; Wang, He-Yao(hywang@simm.ac.cn) ; Ding, Ning(dingning@fudan.edu.cn) |
| 英文摘要 | Fatty acid-binding protein 4 (FABP4) and fatty acid-binding protein 5 (FABP5) are promising therapeutic targets for the treatment of various metabolic diseases. However, the weak potency, low selectivity over FABP3, or poor pharmacokinetic profiles of currently reported dual FABP4/5 inhibitors impeded further research. Here, we described the characterization of a series of dual FABP4/5 inhibitors with improved metabolic stabilities and physicochemical properties based on our previous studies. Among the compounds, D9 and E1 exhibited good inhibitory activities against FABP4/5 and favorable selectivity over FABP3 in vitro. In cell-based assays, D9 and E1 exerted a decrease of FABP4 secretion, a strong anti-lipolytic effect in mature adipocytes, and suppression of MCP-1 expression in THP-1 macrophages. Moreover, D9 and E1 possessed good metabolic stabilities in mouse hepatic microsomes and acceptable pharmacokinetics profiles in ICR mice. Further in vivo experiments showed that D9 and E1 could potently decrease serum FABP4 levels and ameliorate glucose metabolism disorders in obese diabetic db/db mice. These results demonstrated that D9 and E1 could serve as lead compounds for the development of novel anti-diabetic drugs. (C) 2021 Elsevier Masson SAS. All rights reserved. |
| WOS关键词 | ACID-BINDING PROTEIN ; INSULIN-SECRETION ; APOLIPOPROTEIN-E ; OBESITY ; AP2 ; ADIPOKINE ; GLUCOSE ; ATHEROSCLEROSIS ; METABOLISM ; MECHANISMS |
| 资助项目 | National Natural Science Foundation of China[81973178] ; National Natural Science Foundation of China[81773576] ; National Key R&D Program of China[2018YFC0310905] ; Personalized Medicines-Molecular Signature-based Drug Discovery and Development, Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12040336] |
| WOS研究方向 | Pharmacology & Pharmacy |
| 语种 | 英语 |
| WOS记录号 | WOS:000703110000049 |
| 出版者 | ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER |
| 源URL | [http://119.78.100.183/handle/2S10ELR8/297539]  |
| 专题 | 新药研究国家重点实验室 |
| 通讯作者 | Li, Ying-Xia; Wang, He-Yao; Ding, Ning |
| 作者单位 | 1.Fudan Univ, Sch Pharm, Shanghai 201203, Peoples R China 2.Chinese Acad Sci, Shanghai Inst Mat Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China 3.Univ Chinese Acad Sci, Beijing 100049, Peoples R China |
| 推荐引用方式 GB/T 7714 | He, Yu-Long,Chen, Meng-Ting,Wang, Ting,et al. Development of FABP4/5 inhibitors with potential therapeutic effect on type 2 Diabetes Mellitus[J]. EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,2021,224:14. |
| APA | He, Yu-Long.,Chen, Meng-Ting.,Wang, Ting.,Zhang, Ming-Ming.,Li, Ying-Xia.,...&Ding, Ning.(2021).Development of FABP4/5 inhibitors with potential therapeutic effect on type 2 Diabetes Mellitus.EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY,224,14. |
| MLA | He, Yu-Long,et al."Development of FABP4/5 inhibitors with potential therapeutic effect on type 2 Diabetes Mellitus".EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY 224(2021):14. |
入库方式： OAI收割
来源：上海药物研究所
浏览0
下载0
收藏0
其他版本
除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。